Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

NCT03746431 is registered in ClinicalTrials.gov with Fusion Pharmaceuticals Inc. as lead sponsor.

NCT NCT03746431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03746431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
Lead sponsor
Fusion Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 17, 2019
Completion date
December 3, 2025
Enrollment
78 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma, advanced solid tumours, breast cancer, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma (hnscc), her2-negative breast cancer, ovarian cancer, triple negative breast cancer (tnbc), uveal melanoma